Jeanne Hendrickson, MD

• Akiko Iwasaki
• Alessandro Santin
• Alexa Siddon
• Alexander B. Pine
• Alfred Lee
• Amer Zeidan
• Barbara Kazmierczak
• Chad Binns
• Christopher Kerantzas
• Christopher Tormey
• Daniel Zelterman
• David Peaper
• Ellen F Foxman
• Fangyong Li
• George Goshua
• Jane O'Bryan
• Jill Lacy
• John D Roberts
• Katharine Henderson
• Lauren Hachmann Sansing
• Lesley Devine
• Lohith Gowda
• Mahalia S. Desruisseaux
• Manoj M Pillai
• Marwan Mikheal Azar
• Maudry Laurent-Rolle
• Miriam Treggiari
• Nataliya Sostin
• Neima Briggs
• Nikolai Podoltsev
• Noffar Bar
• Oliver Karam
• Peter James Krause
• Raisa Balbuena-Merle
• Ronald George Hauser
• Sabrina Browning
• Shana Gleeson
• Sheela Shenoi
• Stuart Seropian
• Wade Schulz

Anemia, Sickle Cell; Blood Transfusion; Hematology; Immune Tolerance; Plasmapheresis; Pregnancy Complications, Hematologic; Immunity, Humoral; Transfusion Medicine

• Chapter 7 Consent and an approach to the management of acute and chronic transfusion reactionsHendrickson J, Lieberman L. Chapter 7 Consent and an approach to the management of acute and chronic transfusion reactions. 2024, 113-124. DOI: 10.1016/b978-0-323-90459-9.00006-2.
• P‐CB‐23 | Transfused RBCs Are Weak Inducers of IgG Class‐Switching Due to Inefficient Induction of CD4+ T‐Cell HelpMedved J, Shah N, Hester B, Burnett E, Boscia A, Niebuhr C, Santhanakrishnan M, Zimring J, Hendrickson J, Luckey C. P‐CB‐23 | Transfused RBCs Are Weak Inducers of IgG Class‐Switching Due to Inefficient Induction of CD4+ T‐Cell Help. Transfusion 2023, 63: 161a-161a. DOI: 10.1111/trf.206_17554.
• P‐CB‐21 | RBC Alloimmunization Responder Type and COVID‐19 Vaccine IgG Response in Patients with Sickle Cell DiseaseNakahara H, Cheedarla N, Verkerke H, Cheedarla S, Wu S, Hendrickson J, Roback J, Neish A, Fasano R, Stowell S. P‐CB‐21 | RBC Alloimmunization Responder Type and COVID‐19 Vaccine IgG Response in Patients with Sickle Cell Disease. Transfusion 2023, 63: 159a-160a. DOI: 10.1111/trf.204_17554.
• Antibody-mediated antigen loss switches augmented immunity to antibody-mediated immunosuppressionJajosky R, Patel K, Allen J, Zerra P, Chonat S, Ayona D, Maier C, Morais D, Wu S, Luckey C, Eisenbarth S, Roback J, Fasano R, Josephson C, Manis J, Chai L, Hendrickson J, Hudson K, Arthur C, Stowell S. Antibody-mediated antigen loss switches augmented immunity to antibody-mediated immunosuppression. Blood 2023, 142: 1082-1098. PMID: 37363865, DOI: 10.1182/blood.2022018591.
• Introduction to a How I Treat series on consultative hematology for inpatientsHendrickson J, Ortel T. Introduction to a How I Treat series on consultative hematology for inpatients. Blood 2023, 142: 751-752. PMID: 37167420, DOI: 10.1182/blood.2023019877.
• Associations of donor, component, and recipient factors on hemoglobin increments following red blood cell transfusion in very low birth weight infantsDeSimone R, Plimier C, Goel R, Hendrickson J, Josephson C, Patel R, Sola‐Visner M, Roubinian N. Associations of donor, component, and recipient factors on hemoglobin increments following red blood cell transfusion in very low birth weight infants. Transfusion 2023, 63: 1424-1429. PMID: 37387597, PMCID: PMC10530070, DOI: 10.1111/trf.17468.
• Enhanced IgG immune response to COVID‐19 vaccination in patients with sickle cell diseaseNakahara H, Cheedarla N, Verkerke H, Cheedarla S, Wu S, Hendrickson J, Chang A, McLemore M, Rassi F, Roback J, Neish A, Fasano R, Stowell S. Enhanced IgG immune response to COVID‐19 vaccination in patients with sickle cell disease. British Journal Of Haematology 2023, 202: 937-941. PMID: 37287128, DOI: 10.1111/bjh.18899.
• Transfusion therapy for sickle cell disease: what's new?Chou S, Hendrickson J, Hendrickson J, Fasano R. Transfusion therapy for sickle cell disease: what's new? Blood Advances 2023, 7: 2551-2553. PMID: 36562748, PMCID: PMC10242629, DOI: 10.1182/bloodadvances.2022009283.
• Epidemiological and clinical features, therapeutic strategies and outcomes in patients with hyperhaemolysis: A systematic reviewJacobs J, Stephens L, Allen E, Binns T, Booth G, Hendrickson J, Karafin M, Tormey C, Woo J, Adkins B. Epidemiological and clinical features, therapeutic strategies and outcomes in patients with hyperhaemolysis: A systematic review. British Journal Of Haematology 2023, 201: 1025-1032. PMID: 37074146, DOI: 10.1111/bjh.18825.
• Associations between ABO non‐identical platelet transfusions and patient outcomes—A multicenter retrospective analysisBougie D, Reese S, Birch R, Bookwalter D, Mitchell P, Roh D, Kreuziger L, Cable R, Goel R, Gottschall J, Hauser R, Hendrickson J, Hod E, Josephson C, Kahn S, Kleinman S, Mast A, Ness P, Roubinian N, Sloan S, Study‐IV‐Pediatric F. Associations between ABO non‐identical platelet transfusions and patient outcomes—A multicenter retrospective analysis. Transfusion 2023, 63: 960-972. PMID: 36994786, PMCID: PMC10175171, DOI: 10.1111/trf.17319.
• Class switching is differentially regulated in RBC alloimmunization and vaccinationPrakash A, Medved J, Arneja A, Niebuhr C, Li A, Tarrah S, Boscia A, Burnett E, Singh A, Salazar J, Xu W, Santhanakrishnan M, Hendrickson J, Luckey C. Class switching is differentially regulated in RBC alloimmunization and vaccination. Transfusion 2023, 63: 826-838. PMID: 36907655, DOI: 10.1111/trf.17301.
• Storage differentially impacts alloimmunization to distinct red cell antigens following transfusion in miceMaier C, Jajosky R, Patel S, Verkerke H, Fuller M, Allen J, Zerra P, Fasano R, Chonat S, Josephson C, Gibb D, Eisenbarth S, Luckey C, Hudson K, Hendrickson J, Arthur C, Stowell S. Storage differentially impacts alloimmunization to distinct red cell antigens following transfusion in mice. Transfusion 2023, 63: 457-462. PMID: 36708051, PMCID: PMC10414794, DOI: 10.1111/trf.17251.
• Prior Immunization to an Intracellular Antigen Enhances Subsequent Red Blood Cell Alloimmunization in MiceJajosky R, Jajosky R, Patel S, Wu S, Patel K, Patel K, Covington M, Covington M, Vallecillo-Zúniga M, Vallecillo-Zúniga M, Ayona D, Bennett A, Luckey C, Luckey C, Hudson K, Hendrickson J, Hendrickson J, Eisenbarth S, Eisenbarth S, Josephson C, Zerra P, Stowell S, Arthur C. Prior Immunization to an Intracellular Antigen Enhances Subsequent Red Blood Cell Alloimmunization in Mice. Blood 2023, 141: 2642-2653. PMID: 36638335, PMCID: PMC10356576, DOI: 10.1182/blood.2022016588.
• SRSF2 or TET2 Mutations in Patients with MDS Predict Increased Red Blood Cell AlloimmunizationGuarente J, Hendrickson J, Li F, Parziale S, Tormey C, Siddon A. SRSF2 or TET2 Mutations in Patients with MDS Predict Increased Red Blood Cell Alloimmunization. Blood 2022, 140: 5706-5707. DOI: 10.1182/blood-2022-169888.
• A US-Wide Red Blood Cell Alloantibody Exchange Can Decrease Mortality and Produce Cost Savings in the Care of Alloimmunized Patients with Sickle Cell DiseaseGoshua G, Hauser R, Tormey C, Pandya A, Hendrickson J. A US-Wide Red Blood Cell Alloantibody Exchange Can Decrease Mortality and Produce Cost Savings in the Care of Alloimmunized Patients with Sickle Cell Disease. Blood 2022, 140: 2147-2148. DOI: 10.1182/blood-2022-169099.
• Antibody-Mediated Antigen Loss Can Switch an Augmented Immune Response to Antibody-Mediated ImmunosuppressionJajosky R, Allen J, Zerra P, Maier C, Chonat S, Luckey C, Roback J, Fasano R, Josephson C, Manis J, Chai L, Hendrickson J, Hudson K, Arthur C, Stowell S. Antibody-Mediated Antigen Loss Can Switch an Augmented Immune Response to Antibody-Mediated Immunosuppression. Blood 2022, 140: 73-74. DOI: 10.1182/blood-2022-170081.
• Assessment of polymicrobial interactions in bacterial isolates from transfused platelet units associated with sepsisKerantzas CA, Merwede J, Snyder EL, Hendrickson JE, Tormey CA, Kazmierczak BI, Peaper DR. Assessment of polymicrobial interactions in bacterial isolates from transfused platelet units associated with sepsis. Transfusion 2022, 62: 2458-2463. PMID: 36178430, DOI: 10.1111/trf.17136.
• FcγRIV is required for IgG2c mediated enhancement of RBC alloimmunizationQiu A, Miller A, Dei Zotti F, Santhanakrishnan M, Hendrickson JE, Tredicine M, Stowell SR, Luckey CJ, Zimring JC, Hudson KE. FcγRIV is required for IgG2c mediated enhancement of RBC alloimmunization. Frontiers In Immunology 2022, 13: 972723. PMID: 36189253, PMCID: PMC9519184, DOI: 10.3389/fimmu.2022.972723.
• Transfusion in infants and childrenHendrickson J, Josephson C. Transfusion in infants and children. 2022, 381-391. DOI: 10.1002/9781119719809.ch34.
• Clodronate inhibits alloimmunization against distinct red blood cell alloantigens in miceArthur CM, Patel SR, Sharma A, Zerra PE, Chonat S, Jajosky RP, Fasano RM, Patel R, Bennett A, Zhou X, Luckey CJ, Hudson KE, Eisenbarth SC, Josephson CD, Roback JD, Hendrickson JE, Stowell SR. Clodronate inhibits alloimmunization against distinct red blood cell alloantigens in mice. Transfusion 2022, 62: 948-953. PMID: 35470900, PMCID: PMC9491148, DOI: 10.1111/trf.16872.
• The Recipient Epidemiology and Donor Evaluation Study‐IV‐Pediatric (REDS‐IV‐P): A research program striving to improve blood donor safety and optimize transfusion outcomes across the lifespanJosephson CD, Glynn S, Mathew S, Birch R, Bakkour S, Kreuziger L, Busch MP, Chapman K, Dinardo C, Hendrickson J, Hod EA, Kelly S, Luban N, Mast A, Norris P, Custer B, Sabino E, Sachais B, Spencer BR, Stone M, Kleinman S, for the National Heart L. The Recipient Epidemiology and Donor Evaluation Study‐IV‐Pediatric (REDS‐IV‐P): A research program striving to improve blood donor safety and optimize transfusion outcomes across the lifespan. Transfusion 2022, 62: 982-999. PMID: 35441384, PMCID: PMC9353062, DOI: 10.1111/trf.16869.
• International guidelines regarding the role of IVIG in the management of Rh‐ and ABO‐mediated haemolytic disease of the newbornLieberman L, Lopriore E, Baker JM, Bercovitz RS, Christensen RD, Crighton G, Delaney M, Goel R, Hendrickson JE, Keir A, Landry D, La Rocca U, Lemyre B, Maier RF, Muniz‐Diaz E, Nahirniak S, New HV, Pavenski K, Santos M, Ramsey G, Shehata N, Guidelines F. International guidelines regarding the role of IVIG in the management of Rh‐ and ABO‐mediated haemolytic disease of the newborn. British Journal Of Haematology 2022, 198: 183-195. PMID: 35415922, PMCID: PMC9324942, DOI: 10.1111/bjh.18170.
• Innate and Adaptive Immunity to Transfused Allogeneic RBCs in Mice Requires MyD88.Soldatenko A, Hoyt LR, Xu L, Calabro S, Lewis SM, Gallman AE, Hudson KE, Stowell SR, Luckey CJ, Zimring JC, Liu D, Santhanakrishnan M, Hendrickson JE, Eisenbarth SC. Innate and Adaptive Immunity to Transfused Allogeneic RBCs in Mice Requires MyD88. The Journal Of Immunology 2022, 208: 991-997. PMID: 35039331, PMCID: PMC10107373, DOI: 10.4049/jimmunol.2100784.
• Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized PatientsOrtigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, Li Y, Wu D, Cobb GF, Baptiste G, O’Keeffe M, Corpuz MO, Ostrosky-Zeichner L, Amin A, Zacharioudakis IM, Jayaweera DT, Wu Y, Philley JV, Devine MS, Desruisseaux MS, Santin AD, Anjan S, Mathew R, Patel B, Nigo M, Upadhyay R, Kupferman T, Dentino AN, Nanchal R, Merlo CA, Hager DN, Chandran K, Lai JR, Rivera J, Bikash CR, Lasso G, Hilbert TP, Paroder M, Asencio AA, Liu M, Petkova E, Bragat A, Shaker R, McPherson DD, Sacco RL, Keller MJ, Grudzen CR, Hochman JS, Pirofski LA, Rahman F, Ajayi A, Rodriguez S, Ledesma A, Keeling D, Rappoport N, Ebel S, Kim J, Chang M, Chan K, Patel P, Martocci A, Dave S, Darwish Y, Taveras M, Shoyelu V, Xin P, Iturrate E, Moldolsky L, Raimondo B, Mendez S, Hughes P, Sterling S, Lord A, Yaghi S, Veloso K, Sheikh M, Visconti-Ferrara E, Fleming A, Youn H, Jane Fran B, Medina R, McKell R, Khan S, Hamilton T, Sanchez C, Patel N, Cleare L, Vergnolle O, Nakouzi A, Quevedo G, Bortz R, Wirchnianski A, Florez C, Babb R, Ayala J, Tsagaris K, James A, Eke I, Obeidallah A, Sandu O, Sohval S, Serrano-Rahman L, Uehlinger J, Bartash R, Al-Abduladheem A, Gendlina I, Sheridan C, Bortnick A, Eichler J, Kaufman R, Yukelis S, Pennock M, Goggin M, Shen C, Annam J, Khokhar A, Barboto D, Lally B, Lee A, Lee M, Yang X, Allen S, Malaviya A, Moussa O, Park R, Sample R, Bae A, Benoni G, Boerger L, Baker L, Luther M, Ameti L, Briggs N, Golden M, Gormally M, Huang G, Johnson R, Morrison A, Montagna-Hill M, Rivera B, Cortezzo G, Debski K, Nicoletti, DeBenedictis K, Davis R, Marshall C, Duque Cuartas M, Beauchamps L, Bertran-Lopez J, Gonzales Zamora J, Delgado-Lelievre M, Dominguez S, Lee C, Kusack H, Karakeshishyan V, Hajaz A, Deniz D, Garcia G, Dae K, Blenet P, Jaffe D, Olson L, Sabogal D, Blust O, Del Prete Perez V, Bornia C, Rodriguez-Perez V, Calderon V, Ramdev R, Jolly A, Guzman I, Guerra R, Brito S, Hobbs R, Denham R, Dick J, Hernandez M, Nielsen L, Anjum S, Mader S, Stutz T, Mammadova M, Nichols P, Khan T, Boktour M, Castaneda B, Benitez B, Hinojosa E, Guerra B, Ortiz A, Hebbeler-Clark R, McShane P, Hibbard R, Hawkins B, Dohanich E, Wadle C, Greenlee K, Brooks J, Herrick C, Gode A, Bergl P, Hu K, Patel J, Srinivasan S, Graf J, Klis C, Reimer K, Carpenter E, Naczek C, Petersen R, Dex R, Drossart J, Zelten J, Brummitt C, Liang M, Yanny L, Dennison G, Runningen P, Brzezinski B, Fiebig S, Naczek C, Kasdorf M, Parameswaran L, Corcoran A, Rohatgi A, Wronska M, Wu X, Srinivasan R, Deng F, Filardo T, Pendse J, Blaser S, Whyte O, Gallagher J, Thomas O, Ramos D, Sturm-Reganato C, Fong C, Daus I, Payoen A, Chiofolo J, Friedman M, Wu D, Jacobson J, Schneider J, Sarwar U, Wang H, Huebinger R, Dronavalli G, Bai Y, Grimes C, Eldin K, Umana V, Martin J, Heath T, Bello F, Ransford D, Laurent-Rolle M, Shenoi S, Akide-Ndunge O, Thapa B, Peterson J, Knauf K, Patel S, Cheney L, Tormey C, Hendrickson J. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients. JAMA Internal Medicine 2022, 182: 115-126. PMID: 34901997, PMCID: PMC8669605, DOI: 10.1001/jamainternmed.2021.6850.
• Donor genetic and non-genetic factors affecting red blood cell transfusion effectivenessRoubinian NH, Reese SE, Qiao H, Plimier C, Fang F, Page GP, Cable RG, Custer B, Gladwin MT, Goel R, Harris B, Hendrickson JE, Kanias T, Kleinman S, Mast AE, Sloan SR, Spencer BR, Spitalnik SL, Busch MP, Hod EA, . Donor genetic and non-genetic factors affecting red blood cell transfusion effectiveness. JCI Insight 2022, 7: e152598. PMID: 34793330, PMCID: PMC8765041, DOI: 10.1172/jci.insight.152598.
• Autologous hematopoietic stem cell product contaminated with Salmonella due to occult salmonellosis in an asymptomatic donorJacobs JW, Guarente J, Hendrickson JE, Tormey CA, Bar N. Autologous hematopoietic stem cell product contaminated with Salmonella due to occult salmonellosis in an asymptomatic donor. Journal Of Clinical Apheresis 2021, 37: 316-319. PMID: 34953078, DOI: 10.1002/jca.21962.
• Management of hemolytic transfusion reactionsHendrickson JE, Fasano RM. Management of hemolytic transfusion reactions. Hematology 2021, 2021: 704-709. PMID: 34889404, PMCID: PMC8791106, DOI: 10.1182/hematology.2021000308.
• RBC alloimmunization and daratumumab: Are efforts to eliminate interferences and prevent new antibodies necessary?Lee ES, Hendrickson JE, Tormey CA. RBC alloimmunization and daratumumab: Are efforts to eliminate interferences and prevent new antibodies necessary? Transfusion 2021, 61: 3283-3285. PMID: 34767268, DOI: 10.1111/trf.16736.
• Non-crisis related pain occurs in adult patients with sickle cell disease despite chronic red blood cell exchange transfusion therapyCurtis SA, Raisa BM, Roberts JD, Hendrickson JE, Starrels J, Lesley D, Michelle D, Daniel Z, Brandow AM. Non-crisis related pain occurs in adult patients with sickle cell disease despite chronic red blood cell exchange transfusion therapy. Transfusion And Apheresis Science 2021, 61: 103304. PMID: 34782244, PMCID: PMC9838733, DOI: 10.1016/j.transci.2021.103304.
• Therapeutic plasma exchange for peripheral neuropathy associated with trisulfated heparan disaccharide IgM antibodies: A case series of 17 patientsOlsen GM, Tormey CA, Tseng B, Hendrickson JE, Sostin N. Therapeutic plasma exchange for peripheral neuropathy associated with trisulfated heparan disaccharide IgM antibodies: A case series of 17 patients. Journal Of Clinical Apheresis 2021, 37: 13-18. PMID: 34698404, DOI: 10.1002/jca.21944.
• Development of anti-Jk3 associated with silenced Kidd antigen expression and a novel single nucleotide variant of the JK geneManrai PA, Siddon AJ, Hager KM, Hendrickson JE, Keller MA, Tormey CA. Development of anti-Jk3 associated with silenced Kidd antigen expression and a novel single nucleotide variant of the JK gene. Immunohematology 2021, 37: 109-112. PMID: 34591379, DOI: 10.21307/immunohematology-2021-015.
• Transfusion practices for pediatric oncology and hematopoietic stem cell transplantation patients: Data from the National Heart Lung and Blood Institute Recipient Epidemiology and Donor Evaluation Study‐III (REDS‐III)Goel R, Nellis ME, Karam O, Hanson SJ, Tormey CA, Patel RM, Birch R, Sachais BS, Sola‐Visner M, Hauser RG, Luban NLC, Gottschall J, Josephson CD, Hendrickson JE, Karafin MS, Study‐IV‐Pediatric F. Transfusion practices for pediatric oncology and hematopoietic stem cell transplantation patients: Data from the National Heart Lung and Blood Institute Recipient Epidemiology and Donor Evaluation Study‐III (REDS‐III). Transfusion 2021, 61: 2589-2600. PMID: 34455598, DOI: 10.1111/trf.16626.
• Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19Briggs N, Gormally MV, Li F, Browning SL, Treggiari MM, Morrison A, Laurent-Rolle M, Deng Y, Hendrickson JE, Tormey CA, Desruisseaux MS. Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19. PLOS ONE 2021, 16: e0254453. PMID: 34320004, PMCID: PMC8318280, DOI: 10.1371/journal.pone.0254453.
• Altered type 1 interferon responses in alloimmunized and nonalloimmunized patients with sickle cell diseaseMadany E, Lee J, Halprin C, Seo J, Baca N, Majlessipour F, Hendrickson JE, Pepkowitz SH, Hayes C, Klapper E, Gibb DR. Altered type 1 interferon responses in alloimmunized and nonalloimmunized patients with sickle cell disease. EJHaem 2021, 2: 700-710. PMID: 35128535, PMCID: PMC8813163, DOI: 10.1002/jha2.270.
• Potential Implications of a Type 1 Interferon Gene Signature on COVID-19 Severity and Chronic Inflammation in Sickle Cell DiseaseMadany E, Okwan-Duodu D, Balbuena-Merle R, Hendrickson JE, Gibb DR. Potential Implications of a Type 1 Interferon Gene Signature on COVID-19 Severity and Chronic Inflammation in Sickle Cell Disease. Frontiers In Medicine 2021, 8: 679030. PMID: 34368185, PMCID: PMC8339405, DOI: 10.3389/fmed.2021.679030.
• Transfusion Practices in Pediatric Cardiac Surgery Requiring Cardiopulmonary Bypass: A Secondary Analysis of a Clinical DatabaseHanson SJ, Karam O, Birch R, Goel R, Patel RM, Sola-Visner M, Sachais BS, Hauser RG, Luban NLC, Gottschall J, Josephson CD, Hendrickson JE, Karafin MS, Nellis ME, Lung A. Transfusion Practices in Pediatric Cardiac Surgery Requiring Cardiopulmonary Bypass: A Secondary Analysis of a Clinical Database. Pediatric Critical Care Medicine 2021, 22: 978-987. PMID: 34261944, PMCID: PMC8570986, DOI: 10.1097/pcc.0000000000002805.
• The lysophospholipid‐binding molecule CD1D is not required for the alloimmunization response to fresh or stored RBCs in mice despite RBC storage driving alterations in lysophospholipidsMedved J, Knott BM, Tarrah SN, Li AN, Shah N, Moscovich TC, Boscia AR, Salazar JE, Santhanakrishnan M, Hendrickson JE, Fu X, Zimring JC, Luckey CJ. The lysophospholipid‐binding molecule CD1D is not required for the alloimmunization response to fresh or stored RBCs in mice despite RBC storage driving alterations in lysophospholipids. Transfusion 2021, 61: 2169-2178. PMID: 34181769, PMCID: PMC8856511, DOI: 10.1111/trf.16554.
• Complement Plays a Critical Role in Inflammation-Induced Immunoprophylaxis Failure in MiceEscamilla-Rivera V, Santhanakrishnan M, Liu J, Gibb DR, Forsmo JE, Foxman EF, Eisenbarth SC, Luckey CJ, Zimring JC, Hudson KE, Stowell SR, Hendrickson JE. Complement Plays a Critical Role in Inflammation-Induced Immunoprophylaxis Failure in Mice. Frontiers In Immunology 2021, 12: 704072. PMID: 34249009, PMCID: PMC8270673, DOI: 10.3389/fimmu.2021.704072.
• Transfusion practices in a large cohort of hospitalized childrenNellis ME, Goel R, Hendrickson JE, Birch R, Patel RM, Karafin MS, Hanson SJ, Sachais BS, Hauser RG, Luban NLC, Gottschall J, Sola‐Visner M, Josephson CD, Karam O, Study‐IV‐Pediatric F. Transfusion practices in a large cohort of hospitalized children. Transfusion 2021, 61: 2042-2053. PMID: 33973660, DOI: 10.1111/trf.16443.
• Marginal zone B cells mediate a CD4 T-cell-dependent extrafollicular antibody response following RBC transfusion in mice.Zerra PE, Patel SR, Jajosky RP, Arthur CM, McCoy JW, Allen JWL, Chonat S, Fasano RM, Roback JD, Josephson CD, Hendrickson J, Stowell SR. Marginal zone B cells mediate a CD4 T-cell-dependent extrafollicular antibody response following RBC transfusion in mice. Blood 2021, 138: 706-721. PMID: 33876205, PMCID: PMC8394907, DOI: 10.1182/blood.2020009376.
• Variation in Neonatal Transfusion PracticePatel RM, Hendrickson JE, Nellis ME, Birch R, Goel R, Karam O, Karafin MS, Hanson SJ, Sachais BS, Hauser RG, Luban NLC, Gottschall J, Josephson CD, Sola-Visner M, National Heart L, Mast A, Hod E, Custer B, Vichinsky E, Spencer B, Mathew S, Harris D, Busch M, Norris P, Ness P, Kleinman S, Tamburro R, Glynn S, Malkin K. Variation in Neonatal Transfusion Practice. The Journal Of Pediatrics 2021, 235: 92-99.e4. PMID: 33836184, PMCID: PMC8316298, DOI: 10.1016/j.jpeds.2021.04.002.
• Optimization of repeat plerixafor dosing for autologous peripheral blood stem-cell collectionGupta GK, Perreault S, Seropian SE, Tormey CA, Hendrickson JE. Optimization of repeat plerixafor dosing for autologous peripheral blood stem-cell collection. Transfusion And Apheresis Science 2021, 60: 103069. PMID: 33546988, DOI: 10.1016/j.transci.2021.103069.
• Pediatric Hemovigilance and Adverse Transfusion ReactionsSostin N, Hendrickson JE. Pediatric Hemovigilance and Adverse Transfusion Reactions. Clinics In Laboratory Medicine 2020, 41: 51-67. PMID: 33494885, DOI: 10.1016/j.cll.2020.10.004.
• Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpuraGoshua G, Sinha P, Hendrickson J, Tormey C, Bendapudi PK, Lee AI. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood 2020, 137: 969-976. PMID: 33280030, PMCID: PMC7918179, DOI: 10.1182/blood.2020006052.
• Red blood cell alloimmunization and sickle cell disease: a narrative review on antibody inductionHendrickson JE. Red blood cell alloimmunization and sickle cell disease: a narrative review on antibody induction. Annals Of Blood 2020, 5: 33-33. PMID: 33554044, PMCID: PMC7861514, DOI: 10.21037/aob-2020-scd-01.
• Parasite burden and red blood cell exchange transfusion for babesiosisO'Bryan J, Gokhale A, Hendrickson JE, Krause PJ. Parasite burden and red blood cell exchange transfusion for babesiosis. Journal Of Clinical Apheresis 2020, 36: 127-134. PMID: 33179803, PMCID: PMC9517950, DOI: 10.1002/jca.21853.
• Factor V activity in apheresis platelets: Implications for management of FV deficiencyGupta GK, Hendrickson JE, Bahel P, Siddon AJ, Rinder HM, Tormey CA. Factor V activity in apheresis platelets: Implications for management of FV deficiency. Transfusion 2020, 61: 405-409. PMID: 33166428, DOI: 10.1111/trf.16179.
• Use of Convalescent Plasma Therapy in Severe Coronavirus Disease 2019: The Yale-New Haven Health System ExperienceBrowning S, Gormally M, Briggs N, Li M, Zakko A, Laurent-Rolle M, Ladines-Lim J, Morrison A, Kandel P, Khan M, McLeod G, Buller G, Owusu K, Treggiari M, Hendrickson J, Tormey C, Desruisseaux M. Use of Convalescent Plasma Therapy in Severe Coronavirus Disease 2019: The Yale-New Haven Health System Experience. Blood 2020, 136: 39-40. PMCID: PMC8330251, DOI: 10.1182/blood-2020-137352.
• Cost Effectiveness of Caplacizumab in Acquired Thrombotic Thrombocytopenic PurpuraGoshua G, Sinha P, Hendrickson J, Tormey C, Bendapudi P, Lee A. Cost Effectiveness of Caplacizumab in Acquired Thrombotic Thrombocytopenic Purpura. Blood 2020, 136: 18-19. DOI: 10.1182/blood-2020-138515.
• Optimization of Plerixafor Utilization Based on Peripheral Blood CD34+ Count for Autologous Peripheral Blood Stem-Cell CollectionGupta G, Perreault S, Seropian S, Tormey C, Hendrickson J. Optimization of Plerixafor Utilization Based on Peripheral Blood CD34+ Count for Autologous Peripheral Blood Stem-Cell Collection. Blood 2020, 136: 41-41. DOI: 10.1182/blood-2020-140171.
• Type I Interferon Gene Signature in Peripheral Blood Mononuclear Cells of Sickle Cell Disease Patients and a Connection to RBC AlloimmunizationMadany E, Lee J, Hendrickson J, Gibb D. Type I Interferon Gene Signature in Peripheral Blood Mononuclear Cells of Sickle Cell Disease Patients and a Connection to RBC Alloimmunization. Blood 2020, 136: 26-27. DOI: 10.1182/blood-2020-142935.
• Assessment of Factor V Activity in Apheresis Platelet Units: Implications for Management of FV DeficiencyGupta G, Hendrickson J, Bahel P, Siddon A, Rinder H, Tormey C. Assessment of Factor V Activity in Apheresis Platelet Units: Implications for Management of FV Deficiency. American Journal Of Clinical Pathology 2020, 154: s6-s7. DOI: 10.1093/ajcp/aqaa137.011.
• Co-Culture of Acinetobacter calcoaceticus-baumannii complex and Staphylococcus saprophyticus Supports Simple Point Contamination Model in Recent Cases of Transfusion-Related SepsisKerantzas C, Merwede J, Snyder E, Hendrickson J, Tormey C, Kazmierczak B, Peaper D. Co-Culture of Acinetobacter calcoaceticus-baumannii complex and Staphylococcus saprophyticus Supports Simple Point Contamination Model in Recent Cases of Transfusion-Related Sepsis. American Journal Of Clinical Pathology 2020, 154: s14-s14. DOI: 10.1093/ajcp/aqaa137.025.
• Passive Transfer Of Allo-Antibodies Following Rhig Administration Given For Rh-Mismatched Platelets ProphylaxisSostin N, Hendrickson J, Balbuena-Merle R, Tormey C. Passive Transfer Of Allo-Antibodies Following Rhig Administration Given For Rh-Mismatched Platelets Prophylaxis. American Journal Of Clinical Pathology 2020, 154: s158-s159. DOI: 10.1093/ajcp/aqaa161.346.
• Poly(I:C) causes failure of immunoprophylaxis to red blood cells expressing the KEL glycoprotein in miceEscamilla-Rivera V, Liu J, Gibb DR, Santhanakrishnan M, Liu D, Forsmo JE, Eisenbarth S, Foxman EF, Stowell SR, Luckey CJ, Zimring JC, Hudson KE, Hendrickson J. Poly(I:C) causes failure of immunoprophylaxis to red blood cells expressing the KEL glycoprotein in mice. Blood 2020, 135: 1983-1993. PMID: 32266378, PMCID: PMC7256361, DOI: 10.1182/blood.2020005018.
• A potential association of an interferon gene signature with RBC alloimmunization in sickle cell diseaseMadany E, Kadi N, Pandya S, Hendrickson J, Gibb D. A potential association of an interferon gene signature with RBC alloimmunization in sickle cell disease. The Journal Of Immunology 2020, 204: 145.18-145.18. DOI: 10.4049/jimmunol.204.supp.145.18.
• The Presence and Persistence of Pregnancy-Associated Red Blood Cell Alloantibodies in Blood DonorsBalbuena-Merle R, Hauser R, Karafin M, Tan S, Spencer B, Roubinian N, Wu Y, Triulzi D, Kleinman S, Gottschall J, Tormey C, Hendrickson J. The Presence and Persistence of Pregnancy-Associated Red Blood Cell Alloantibodies in Blood Donors. Blood 2019, 134: 2452-2452. DOI: 10.1182/blood-2019-121388.
• Baseline Pain in Adults with Sickle Cell Disease Can be Neuropathic or Nociceptive and Outcomes Differ between Pain TypesCurtis S, Forray A, Hendrickson J, Roberts J. Baseline Pain in Adults with Sickle Cell Disease Can be Neuropathic or Nociceptive and Outcomes Differ between Pain Types. Blood 2019, 134: 1028-1028. DOI: 10.1182/blood-2019-129106.
• Increased Expression of Type 1 Interferon Stimulated Genes in Sickle Cell Disease and a Potential Association with RBC AlloimmunizationMadany E, El Kadi N, Kadi N, Pandya S, Hendrickson J, Gibb D. Increased Expression of Type 1 Interferon Stimulated Genes in Sickle Cell Disease and a Potential Association with RBC Alloimmunization. Blood 2019, 134: 716-716. DOI: 10.1182/blood-2019-124899.
• Recipient factors influencing red blood cell alloimmunizationHendrickson J. Recipient factors influencing red blood cell alloimmunization. ISBT Science Series 2019, 15: 194-200. DOI: 10.1111/voxs.12485.
• Restrictive Transfusions in the Era of Pathogen-Inactivated Platelets: A Single Center ExperienceShallis R, Gleeson S, Chokr N, Fangyong L, Wei W, Azar M, Schulz W, Summers D, Hendrickson J, Foss F, Isufi I, Kim T, Pillai M, Snyder E, Seropian S, Gowda L. Restrictive Transfusions in the Era of Pathogen-Inactivated Platelets: A Single Center Experience. Transplantation And Cellular Therapy 2019, 25: s365. DOI: 10.1016/j.bbmt.2018.12.591.
• Chapter 57 Platelet Transfusion Refractory PatientsTormey C, Hendrickson J. Chapter 57 Platelet Transfusion Refractory Patients. 2019, 361-364. DOI: 10.1016/b978-0-12-813726-0.00057-x.
• Chapter 49 Neonatal and Pediatric Transfusion MedicineZerra P, Hendrickson J, Josephson C. Chapter 49 Neonatal and Pediatric Transfusion Medicine. 2019, 295-299. DOI: 10.1016/b978-0-12-813726-0.00049-0.
• Chapter 53 Transfusion Management of Patients Undergoing Hematopoietic Stem Cell and Solid Organ TransplantationRutter S, Hendrickson J. Chapter 53 Transfusion Management of Patients Undergoing Hematopoietic Stem Cell and Solid Organ Transplantation. 2019, 337-341. DOI: 10.1016/b978-0-12-813726-0.00053-2.
• Chapter 56 Management of Patients Who Refuse Blood TransfusionBahar B, Hendrickson J. Chapter 56 Management of Patients Who Refuse Blood Transfusion. 2019, 357-360. DOI: 10.1016/b978-0-12-813726-0.00056-8.
• Chapter 65 Transfusion-Associated Circulatory OverloadGokhale A, Hendrickson J. Chapter 65 Transfusion-Associated Circulatory Overload. 2019, 401-404. DOI: 10.1016/b978-0-12-813726-0.00065-9.
• Chapter 66 Transfusion-Related Acute Lung InjuryGokhale A, Hendrickson J. Chapter 66 Transfusion-Related Acute Lung Injury. 2019, 405-408. DOI: 10.1016/b978-0-12-813726-0.00066-0.
• Elevated Levels of CD64 MFI on Monocyte Subsets Are Associated with a History of Stroke in Sickle Cell DiseaseCurtis S, Balbuena-Merle R, Devine L, Zelterman D, Roberts J, Dearborn-Tomazos J, Sansing L, Hendrickson J. Elevated Levels of CD64 MFI on Monocyte Subsets Are Associated with a History of Stroke in Sickle Cell Disease. Blood 2018, 132: 1093-1093. DOI: 10.1182/blood-2018-99-117504.
• Cost Effectiveness of Rituximab As Adjunctive Therapy in Reducing Apheresis Procedures and Hospital Length of Stay in Relapsed Thrombotic Thrombocytopenic PurpuraGoshua G, Gokhale A, Hendrickson J, Tormey C, Lee A. Cost Effectiveness of Rituximab As Adjunctive Therapy in Reducing Apheresis Procedures and Hospital Length of Stay in Relapsed Thrombotic Thrombocytopenic Purpura. Blood 2018, 132: 3814-3814. DOI: 10.1182/blood-2018-99-113621.
• Influenza Infection Induces RBC Alloimmunization By a Type 1 Interferon Dependent MechanismGibb D, Liu D, Liu J, Santhanakrishnan M, Eisenbarth S, Hendrickson J. Influenza Infection Induces RBC Alloimmunization By a Type 1 Interferon Dependent Mechanism. Blood 2018, 132: 743-743. DOI: 10.1182/blood-2018-99-110884.
• HLA Class I Alloimmunization and Platelet Transfusion Support in HLA-Identical Bone Marrow Transplant for Sickle Cell Disease: A Sickle Transplant Alliance for Research StudyNickel R, Horan J, Abraham A, Qayed M, Haight A, Luban N, Hendrickson J. HLA Class I Alloimmunization and Platelet Transfusion Support in HLA-Identical Bone Marrow Transplant for Sickle Cell Disease: A Sickle Transplant Alliance for Research Study. Blood 2018, 132: 3816-3816. DOI: 10.1182/blood-2018-99-114116.
• 6 A Novel Association Between High Red Blood Cell Alloimmunization Rates and Hereditary Hemorrhagic Telangiectasia (HHT)Zheng Y, Pollak J, Henderson K, Hendrickson J, Tormey C. 6 A Novel Association Between High Red Blood Cell Alloimmunization Rates and Hereditary Hemorrhagic Telangiectasia (HHT). American Journal Of Clinical Pathology 2018, 149: s166-s166. DOI: 10.1093/ajcp/aqx149.375.
• 1 Type I Interferon Is Necessary and Sufficient for Alloimmunization to Transfused KEL-Expressing RBCs in MiceGibb D, Liu J, Natarajan P, Santhanakrishnan M, Madrid D, Eisenbarth S, Zimring J, Iwasaki A, Hendrickson J. 1 Type I Interferon Is Necessary and Sufficient for Alloimmunization to Transfused KEL-Expressing RBCs in Mice. American Journal Of Clinical Pathology 2018, 149: s163-s163. DOI: 10.1093/ajcp/aqx149.370.
• 3 The Importance of CD4 Cells and CD40/CD40 Ligand Interactions in Humoral Immune Responses to Transfused KEL RBCs in MiceMadrid D, Gibb D, Natarajan P, Santhanakrishnan M, Liu J, Hendrickson J. 3 The Importance of CD4 Cells and CD40/CD40 Ligand Interactions in Humoral Immune Responses to Transfused KEL RBCs in Mice. American Journal Of Clinical Pathology 2018, 149: s164-s164. DOI: 10.1093/ajcp/aqx149.372.
• 9 Examining the Correlation Between Microbial Pathogen Sequence Structure and Blood Group Antigen ImmunogenicityBahar B, Baine I, Hendrickson J, Tormey C. 9 Examining the Correlation Between Microbial Pathogen Sequence Structure and Blood Group Antigen Immunogenicity. American Journal Of Clinical Pathology 2018, 149: s167-s168. DOI: 10.1093/ajcp/aqx149.378.
• Chapter 21 Data Interpretation in Laboratory MedicineTormey C, Gehrie E, Pham H, Bucy R, Lorenz R, Zheng X, Hendrickson J. Chapter 21 Data Interpretation in Laboratory Medicine. 2018, 489-510. DOI: 10.1016/b978-0-12-803999-1.00021-3.
• Chapter 4 Common Significant Non-ABO Antibodies and Blood Group Antigen AlloimmunizationBaine I, Hendrickson J, Tormey C. Chapter 4 Common Significant Non-ABO Antibodies and Blood Group Antigen Alloimmunization. 2018, 25-39. DOI: 10.1016/b978-0-323-54458-0.00004-0.
• A patient with oxaliplatin immune-induced syndrome (OIIS) who also developed leucovorin and palonosetron-associated thrombocytopeniaCurtis SA, Curtis BR, Lee AI, Hendrickson JE, Lacy J, Podoltsev NA. A patient with oxaliplatin immune-induced syndrome (OIIS) who also developed leucovorin and palonosetron-associated thrombocytopenia. Hematology 2017, 23: 429-432. PMID: 29281948, DOI: 10.1080/10245332.2017.1419600.
• A multicentre study investigating vital sign changes occurring in complicated and uncomplicated transfusionsGehrie E, Roubinian N, Chowdhury D, Brambilla D, Murphy E, Gottschall J, Wu Y, Ness P, Strauss R, Hendrickson J, Study T. A multicentre study investigating vital sign changes occurring in complicated and uncomplicated transfusions. Vox Sanguinis 2017, 113: 160-169. PMID: 29277907, PMCID: PMC5812819, DOI: 10.1111/vox.12621.
• Red blood cell alloimmunisation: induction of immunity and potential mitigation strategiesHendrickson J. Red blood cell alloimmunisation: induction of immunity and potential mitigation strategies. ISBT Science Series 2017, 13: 105-111. DOI: 10.1111/voxs.12360.
• Transfusion Support of the Patient with Sickle Cell Disease Undergoing TransplantationHendrickson J, Fasano R. Transfusion Support of the Patient with Sickle Cell Disease Undergoing Transplantation. 2017, 111-136. DOI: 10.1007/978-3-319-62328-3_5.
• Interleukin-6 receptor α signaling on CD4+ T cells drives RBC alloantibody generation and T follicular helper cell differentiation in a murine model of RBC alloimmunization.Arneja A, Salazar J, Jiang W, Hendrickson J, Zimring J, Luckey C. Interleukin-6 receptor α signaling on CD4+ T cells drives RBC alloantibody generation and T follicular helper cell differentiation in a murine model of RBC alloimmunization. The Journal Of Immunology 2017, 198: 201.27-201.27. DOI: 10.4049/jimmunol.198.supp.201.27.
• Incidence and clinical characteristics of transfusion‐associated circulatory overload using an active surveillance algorithmRoubinian N, Hendrickson J, Triulzi D, Gottschall J, Chowdhury D, Kor D, Looney M, Matthay M, Kleinman S, Brambilla D, Murphy E, Study‐III T. Incidence and clinical characteristics of transfusion‐associated circulatory overload using an active surveillance algorithm. Vox Sanguinis 2016, 112: 56-63. PMID: 28001313, PMCID: PMC5257198, DOI: 10.1111/vox.12466.
• Determination of Red Blood Cell Alloimmunization Rates in Transfused Patients with Hematologic and Oncologic MalignanciesAsare M, Hendrickson J, Tormey C. Determination of Red Blood Cell Alloimmunization Rates in Transfused Patients with Hematologic and Oncologic Malignancies. Blood 2016, 128: 1463-1463. DOI: 10.1182/blood.v128.22.1463.1463.
• Type 1 Interferon Regulates Inflammation Associated RBC Alloimmunization By Promoting Monocyte-Derived Dendritic Cell Erythrophagocytosis in MiceGibb D, Natarajan P, Liu J, Santhanakrishnan M, Iwasaki A, Hendrickson J. Type 1 Interferon Regulates Inflammation Associated RBC Alloimmunization By Promoting Monocyte-Derived Dendritic Cell Erythrophagocytosis in Mice. Blood 2016, 128: 19-19. DOI: 10.1182/blood.v128.22.19.19.
• Transfusion MedicineHendrickson J, Tormey C. Transfusion Medicine. Hematology/Oncology Clinics Of North America 2016, 30: i. DOI: 10.1016/s0889-8588(16)30041-7.
• Platelet and plasma transfusions for infants and childrenHendrickson J, Josephson C. Platelet and plasma transfusions for infants and children. 2016, 542-548. DOI: 10.1002/9781119013020.ch47.
• North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute LeukemiaPine A, Lee E, Sekeres M, Steensma D, Prebet T, DeZern A, Komrokji R, Litzow M, Luger S, Stone R, Erba H, Garcia-Manero G, Lee A, Podoltsev N, Barbarotta L, Hendrickson J, Gore S, Zeidan A. North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia. Blood 2015, 126: 1138-1138. DOI: 10.1182/blood.v126.23.1138.1138.
• A Novel Network Analysis Tool to Identify Relationships Between Disease States and Risk for RBC AlloimmunizationCelli R, Schulz W, Hendrickson J, Tormey C. A Novel Network Analysis Tool to Identify Relationships Between Disease States and Risk for RBC Alloimmunization. Blood 2015, 126: 2349-2349. DOI: 10.1182/blood.v126.23.2349.2349.
• DOCK8-Deficient Mice Reveal a Crucial Role for Dendritic Cell Activity in the Initiation of the Allogeneic Response to Transfused Red Blood CellsEisenbarth S, Hendrickson J, Calabro S, Gallman A. DOCK8-Deficient Mice Reveal a Crucial Role for Dendritic Cell Activity in the Initiation of the Allogeneic Response to Transfused Red Blood Cells. Blood 2015, 126: 658-658. DOI: 10.1182/blood.v126.23.658.658.
• Anti-RhD Mediates Loss of RhD Antigen Following Anti-RhD InfusionSullivan H, Arthur C, Patel S, Hendrickson J, Lazarus A, Stowell S. Anti-RhD Mediates Loss of RhD Antigen Following Anti-RhD Infusion. Blood 2015, 126: 3570-3570. DOI: 10.1182/blood.v126.23.3570.3570.
• Antigen Density Impacts RBC Survival and Antigen Modulation Following Incompatible RBC TransfusionYoo J, Arthur C, Zerra P, Girard-Pierce K, Hendrickson J, Stowell S. Antigen Density Impacts RBC Survival and Antigen Modulation Following Incompatible RBC Transfusion. Blood 2015, 126: 2350-2350. DOI: 10.1182/blood.v126.23.2350.2350.
• INNATE AND ADAPTIVE IMMUNE RESPONSES TO TRANSFUSED ALLOANTIGENSZimring J, Hudson K, Hendrickson J. INNATE AND ADAPTIVE IMMUNE RESPONSES TO TRANSFUSED ALLOANTIGENS. Pathology 2015, 47: s41. DOI: 10.1097/01.pat.0000461433.20240.46.
• INNATE AND ADAPTIVE IMMUNE RESPONSES TO TRANSFUSED ALLOANTIGENSZimring J, Hudson K, Hendrickson J. INNATE AND ADAPTIVE IMMUNE RESPONSES TO TRANSFUSED ALLOANTIGENS. Pathology 2015, 47: s34. DOI: 10.1097/01.pat.0000461421.80336.37.
• Chronic Inflammatory Autoimmune Disorders Are a Risk Factor for Blood Group Alloimmunization in Transfused PatientsRyder A, Hendrickson J, Tormey C. Chronic Inflammatory Autoimmune Disorders Are a Risk Factor for Blood Group Alloimmunization in Transfused Patients. Blood 2014, 124: 4294-4294. DOI: 10.1182/blood.v124.21.4294.4294.
• Polyclonal Anti-Kel (KELGAM) Prevents Alloimmunization to Transfused Kel RBCs in a Murine ModelStowell S, Arthur C, Girard-Pierce K, Sullivan H, Santhanakrishnan M, Natarajan P, Tormey C, Zimring J, Hendrickson J. Polyclonal Anti-Kel (KELGAM) Prevents Alloimmunization to Transfused Kel RBCs in a Murine Model. Blood 2014, 124: 758-758. DOI: 10.1182/blood.v124.21.758.758.
• NLRP10-Deficient Mice Reveal a Crucial Role for Dendritic Cell Activity in the Initiation of the Allogeneic Response to Transfused Red Blood CellsEisenbarth S, Hendrickson J, Calabro S, Gallman A. NLRP10-Deficient Mice Reveal a Crucial Role for Dendritic Cell Activity in the Initiation of the Allogeneic Response to Transfused Red Blood Cells. Blood 2014, 124: 4113-4113. DOI: 10.1182/blood.v124.21.4113.4113.
• Reticuloendothelial Saturation Dictates the Development of RBC Resistance to Antibody-Mediated Clearance Following Incompatible TransfusionArthur C, Mener A, Patel S, Rodrigues L, Xue C, Nickel R, Zimring J, Hendrickson J, Stowell S. Reticuloendothelial Saturation Dictates the Development of RBC Resistance to Antibody-Mediated Clearance Following Incompatible Transfusion. Blood 2014, 124: 1559-1559. DOI: 10.1182/blood.v124.21.1559.1559.
• CD8+ T Cells Mediate Antibody-Independent Platelet Clearance Following TransfusionPatel S, Arthur C, Rodrigues L, Xue C, Zimring J, Hendrickson J, Stowell S. CD8+ T Cells Mediate Antibody-Independent Platelet Clearance Following Transfusion. Blood 2014, 124: 596-596. DOI: 10.1182/blood.v124.21.596.596.
• Coagulopathy Predicts Mortality in Pediatric Patients with Traumatic Brain InjuryDoshi B, Meeks S, Hendrickson J, Reisner A, Leong T, Winkler A, Meyer E. Coagulopathy Predicts Mortality in Pediatric Patients with Traumatic Brain Injury. Blood 2014, 124: 2891-2891. DOI: 10.1182/blood.v124.21.2891.2891.
• The RBC as a Target of DamageHendrickson J, Tormey C. The RBC as a Target of Damage. 2014, 3068-3080. DOI: 10.1016/b978-0-12-386456-7.06203-1.
• KEL RBC Transfusion Induces IgG Anti-KEL Antibodies Independent Of CD4 T CellsStowell S, Girard-Pierce K, Arthur C, Smith N, Zimring J, Hendrickson J. KEL RBC Transfusion Induces IgG Anti-KEL Antibodies Independent Of CD4 T Cells. Blood 2013, 122: 41-41. DOI: 10.1182/blood.v122.21.41.41.
• Transfusion Of RBCs With Low-Density KEL Induces Tolerance To The KEL AntigenStowell S, Arthur C, Smith N, Girard-Pierce K, Zimring J, Hendrickson J. Transfusion Of RBCs With Low-Density KEL Induces Tolerance To The KEL Antigen. Blood 2013, 122: 1160-1160. DOI: 10.1182/blood.v122.21.1160.1160.
• Alloimmunization To HLA Class I Antigens But Not H-Y Antigens Is Associated With Transfusion In Children With Sickle Cell DiseaseNickel R, Hendrickson J, Kean L, Yee M, McPherson Yee M, Bray R, Gebel H, Miklos D, Horan J. Alloimmunization To HLA Class I Antigens But Not H-Y Antigens Is Associated With Transfusion In Children With Sickle Cell Disease. Blood 2013, 122: 39-39. DOI: 10.1182/blood.v122.21.39.39.
• Storage-Induced Clearance Of RBCs Following Transfusion Occurs Independent Of RBC AgeArthur C, Smith N, Zimring J, Hendrickson J, Stowell S. Storage-Induced Clearance Of RBCs Following Transfusion Occurs Independent Of RBC Age. Blood 2013, 122: 792-792. DOI: 10.1182/blood.v122.21.792.792.
• Red Blood Cell Alloimmunization and Hemolytic Disease of the Fetus and Newborn: New Approaches Using Animal ModelsHendrickson J. Red Blood Cell Alloimmunization and Hemolytic Disease of the Fetus and Newborn: New Approaches Using Animal Models. Blood 2013, 122: sci-49-sci-49. DOI: 10.1182/blood.v122.21.sci-49.sci-49.
• Alterations In Specific Immune Cell Subsets In Children With Sickle Cell DiseaseNickel R, Hendrickson J, Horan J, Garrett A, Robertson J, Osunkwo I, Kean L. Alterations In Specific Immune Cell Subsets In Children With Sickle Cell Disease. Blood 2013, 122: 2208-2208. DOI: 10.1182/blood.v122.21.2208.2208.
• Chapter 54 Management of Patients Who Refuse Blood TransfusionHendrickson J. Chapter 54 Management of Patients Who Refuse Blood Transfusion. 2013, 357-360. DOI: 10.1016/b978-0-12-397164-7.00054-9.
• Chapter 51 Transfusion of Patients Undergoing Hematopoietic Stem Cell and Solid Organ TransplantationHendrickson J. Chapter 51 Transfusion of Patients Undergoing Hematopoietic Stem Cell and Solid Organ Transplantation. 2013, 337-342. DOI: 10.1016/b978-0-12-397164-7.00051-3.
• Chapter 64 Transfusion-Related Acute Lung InjuryHendrickson J, Hillyer C. Chapter 64 Transfusion-Related Acute Lung Injury. 2013, 417-420. DOI: 10.1016/b978-0-12-397164-7.00064-1.
• Chapter 63 Transfusion-Associated Circulatory OverloadHendrickson J, Hillyer C. Chapter 63 Transfusion-Associated Circulatory Overload. 2013, 413-415. DOI: 10.1016/b978-0-12-397164-7.00063-x.
• Chapter 55 Platelet Transfusion Refractory PatientsHendrickson J. Chapter 55 Platelet Transfusion Refractory Patients. 2013, 361-365. DOI: 10.1016/b978-0-12-397164-7.00055-0.
• Chapter 47 Neonatal and Pediatric Transfusion MedicineHendrickson J, Josephson C. Chapter 47 Neonatal and Pediatric Transfusion Medicine. 2013, 301-305. DOI: 10.1016/b978-0-12-397164-7.00047-1.
• Development of a Murine Model of Weak Kel: Similarities to Weak Rh(D)Hendrickson J, Smith N, Girard-Pierce K, Tormey C, Henry K, Zimring J, Stowell S. Development of a Murine Model of Weak Kel: Similarities to Weak Rh(D). Blood 2012, 120: 842-842. DOI: 10.1182/blood.v120.21.842.842.
• Marginal Zone B Cells Mediate Alloantibody Formation to a Clinically Significant Human RBC Antigen in a Murine ModelGirard-Pierce K, Stowell S, Smith N, Henry K, Zimring J, Hendrickson J. Marginal Zone B Cells Mediate Alloantibody Formation to a Clinically Significant Human RBC Antigen in a Murine Model. Blood 2012, 120: 843-843. DOI: 10.1182/blood.v120.21.843.843.
• A Genetic Basis for Donor Variation in Generation of Prostaglandins and Leukotrienes in Stored RBCs Using a Mouse ModelZimring J, Smith N, Stowell S, Francis R, Hod E, Hendrickson J, Dumont L, Roback J, Spitalnik S. A Genetic Basis for Donor Variation in Generation of Prostaglandins and Leukotrienes in Stored RBCs Using a Mouse Model. Blood 2012, 120: 844-844. DOI: 10.1182/blood.v120.21.844.844.
• Cellular Protection Against Antibodies Occurs Through a Complement-Independent PathwayStowell S, Liepkalns J, Hendrickson J, Pierce K, Smith N, Zimring J. Cellular Protection Against Antibodies Occurs Through a Complement-Independent Pathway. Blood 2012, 120: 3290-3290. DOI: 10.1182/blood.v120.21.3290.3290.
• Effects of genetic, epigenetic, and environmental factors on alloimmunization to transfused antigens: Current paradigms and future considerationsZimring J, Stowell S, Johnsen J, Hendrickson J. Effects of genetic, epigenetic, and environmental factors on alloimmunization to transfused antigens: Current paradigms and future considerations. Transfusion Clinique Et Biologique 2012, 19: 125-131. PMID: 22682308, DOI: 10.1016/j.tracli.2012.03.002.
• Coagulation, Bleeding, and Blood TransfusionMiller B, Hendrickson J. Coagulation, Bleeding, and Blood Transfusion. 2011, 224-254. DOI: 10.1002/9781444345186.ch11.
• Central T Cell Tolerance and Peripheral B Cell Tolerance for An RBC Autoantigen Are Incomplete in Healthy Mice; Implications for AIHA PathogenesisHudson K, Hendrickson J, Cadwell C, Iwakoshi N, Zimring J. Central T Cell Tolerance and Peripheral B Cell Tolerance for An RBC Autoantigen Are Incomplete in Healthy Mice; Implications for AIHA Pathogenesis. Blood 2011, 118: 693-693. DOI: 10.1182/blood.v118.21.693.693.
• A Novel Murine Model of Pregnancy and Transfusion Induced Anti-Kell RBC AlloimmunizationSmith N, Henry K, Zimring J, Hendrickson J. A Novel Murine Model of Pregnancy and Transfusion Induced Anti-Kell RBC Alloimmunization. Blood 2011, 118: 715-715. DOI: 10.1182/blood.v118.21.715.715.
• Fresh Murine Red Blood Cells Abrogate the Enhanced Alloimmunogenicity of Stored Murine Red Blood CellsHendrickson J, Hod E, Spitalnik S, Zimring J. Fresh Murine Red Blood Cells Abrogate the Enhanced Alloimmunogenicity of Stored Murine Red Blood Cells. Blood 2010, 116: 663-663. DOI: 10.1182/blood.v116.21.663.663.
• Use of mouse models to study the mechanisms and consequences of RBC clearanceHod E, Arinsburg S, Francis R, Hendrickson J, Zimring J, Spitalnik S. Use of mouse models to study the mechanisms and consequences of RBC clearance. Vox Sanguinis 2010, 99: 99-111. PMID: 20345515, PMCID: PMC3580149, DOI: 10.1111/j.1423-0410.2010.01327.x.
• MHC II on transfused murine blood is not required for alloimmunization against MHC IGilson C, Cadwell C, Smith N, Hendrickson J, Zimring J. MHC II on transfused murine blood is not required for alloimmunization against MHC I. Vox Sanguinis 2010, 99: 369-374. PMID: 20546207, PMCID: PMC2955847, DOI: 10.1111/j.1423-0410.2010.01351.x.
• Leukoreduction Decreases Alloimmunogenicity of Transfused Murine HOD RBCs.Hendrickson J, Hod E, Spitalnik S, Hillyer C, Zimring J. Leukoreduction Decreases Alloimmunogenicity of Transfused Murine HOD RBCs. Blood 2009, 114: 640-640. DOI: 10.1182/blood.v114.22.640.640.
• Chapter 47 Transfusion of HIV-positive PatientsHendrickson J, Roback J. Chapter 47 Transfusion of HIV-positive Patients. 2009, 275-278. DOI: 10.1016/b978-0-12-374432-6.00047-6.
• Chapter 48 Management of Patients Who Refuse Blood TransfusionHendrickson J, Roback J. Chapter 48 Management of Patients Who Refuse Blood Transfusion. 2009, 279-282. DOI: 10.1016/b978-0-12-374432-6.00048-8.
• Chapter 49 Platelet Transfusion Refractory PatientsHendrickson J, Roback J. Chapter 49 Platelet Transfusion Refractory Patients. 2009, 283-286. DOI: 10.1016/b978-0-12-374432-6.00049-x.
• Chapter 42 Neonatal and Pediatric Transfusion MedicineHendrickson J, Josephson C. Chapter 42 Neonatal and Pediatric Transfusion Medicine. 2009, 235-239. DOI: 10.1016/b978-0-12-374432-6.00042-7.
• Chapter 57 Transfusion Associated Circulatory OverloadHendrickson J, Hillyer C. Chapter 57 Transfusion Associated Circulatory Overload. 2009, 327-329. DOI: 10.1016/b978-0-12-374432-6.00057-9.
• Chapter 46 Transfusion of Patients Undergoing HPC and Solid-organ TransplantationHendrickson J, Roback J. Chapter 46 Transfusion of Patients Undergoing HPC and Solid-organ Transplantation. 2009, 269-274. DOI: 10.1016/b978-0-12-374432-6.00046-4.
• Chapter 58 Transfusion Related Acute Lung InjuryHendrickson J, Hillyer C. Chapter 58 Transfusion Related Acute Lung Injury. 2009, 331-334. DOI: 10.1016/b978-0-12-374432-6.00058-0.
• A Novel Model of Autoimmunity to Self Red Blood Cell AntigensHendrickson J, Cadwell C, Hillyer C, Zimring J. A Novel Model of Autoimmunity to Self Red Blood Cell Antigens. Blood 2008, 112: 3461-3461. DOI: 10.1182/blood.v112.11.3461.3461.
• Berkeley Mice with Sickle Cell Disease Are Not More Immunizable to Transfused HOD Red Blood Cells Than Sickle Trait Control MiceHendricKson J, Archer D, Perry J, Hillyer C, Zimring J. Berkeley Mice with Sickle Cell Disease Are Not More Immunizable to Transfused HOD Red Blood Cells Than Sickle Trait Control Mice. Blood 2008, 112: 292-292. DOI: 10.1182/blood.v112.11.292.292.
• An Intact Spleen Is Required for Alloimmunization to Transfused Red Blood Cells Due to Intrasplenic Activation of CD4+ T Cells.Hendrickson J, Roback J, Hillyer C, Zimring J. An Intact Spleen Is Required for Alloimmunization to Transfused Red Blood Cells Due to Intrasplenic Activation of CD4+ T Cells. Blood 2007, 110: 453-453. DOI: 10.1182/blood.v110.11.453.453.
• Recipient Inflammation That Increases Alloimmunization Also Enhances Consumption of Transfused RBCs by Dendritic Cells.Hendrickson J, Roback J, Hillyer C, Zimring J. Recipient Inflammation That Increases Alloimmunization Also Enhances Consumption of Transfused RBCs by Dendritic Cells. Blood 2006, 108: 23-23. DOI: 10.1182/blood.v108.11.23.23.
• Lack of Alloantibody Response to Red Blood Cell Antigens in Juvenile Mice Following Transfusion: Non-Immunogenic or Tolerogenic Response?.Hendrickson J, Josephson C, Chadwick T, Zimring J. Lack of Alloantibody Response to Red Blood Cell Antigens in Juvenile Mice Following Transfusion: Non-Immunogenic or Tolerogenic Response?. Blood 2006, 108: 955-955. DOI: 10.1182/blood.v108.11.955.955.
• Host Inflammation Increases Alloimmunization to Transfused Red Blood Cells.Hendrickson J, Chadwick T, Roback J, Hillyer C, Zimring J. Host Inflammation Increases Alloimmunization to Transfused Red Blood Cells. Blood 2005, 106: 1887-1887. DOI: 10.1182/blood.v106.11.1887.1887.